Computational drug discovery pipelines identify NAMPT as a therapeutic target in neuroendocrine prostate cancer.

ABSTRACT: Neuroendocrine prostate cancer (NEPC) is an aggressive advanced subtype of prostate cancer that exhibits poor prognosis and broad resistance to therapies. Currently, few treatment options are available, highlighting a need for new therapeutics to help curb the high mortality rates of this disease. We designed a comprehensive drug discovery pipeline that quickly generates drug candidates ready to be tested. Our method estimated patient response to various therapeutics in three independent prostate cancer patient cohorts and selected robust candidate drugs showing high predicted potency in NEPC tumors. Using this pipeline, we nominated NAMPT as a molecular target to effectively treat NEPC tumors. Our in vitro experiments validated the efficacy of NAMPT inhibitors in NEPC cells. Compared with

SUBMITTER: Zhang W 

PROVIDER: S-EPMC11411198 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature